Radiosensitivity in breast cancer assessed by the Comet and micronucleus assays

CS Djuzenova*, 1, B Mühl1, M Fehn1, U Oppitz1, B Müller1 and M Flentje1

1Klinik für Strahlentherapie der Universität Würzburg, Josef-Schneider-Str. 11, Würzburg D-97080, Germany

Spontaneous and radiation-induced genetic instability of peripheral blood mononuclear cells derived from unselected breast cancer (BC) patients (n = 50) was examined using the single-cell gel electrophoresis (Comet) assay and a modified G2 micronucleus (MN) test. Cells from apparently healthy donors (n = 16) and from cancer patients (n = 9) with an adverse early skin reaction to radiotherapy (RT) served as references. Nonirradiated cells from the three tested groups exhibited similar baseline levels of DNA fragmentation assessed by the Comet assay. Likewise, the Comet analysis of in vitro irradiated (5 Gy) cells did not reveal any significant differences among the three groups with respect to the initial and residual DNA fragmentation, as well as the DNA repair kinetics. The G2 MN test showed that cells from cancer patients with an adverse skin reaction to RT displayed increased frequencies of both spontaneous and radiation-induced MN compared to healthy control or the group of unselected BC patients. Two patients from the latter group developed an increased early skin reaction to RT, which was associated with an increased initial DNA fragmentation in vitro only in one of them. Cells from the other BC patient exhibited a striking slope in the dose–response curve detected by the G2 MN test. We also found that previous RT strongly increased both spontaneous and in vitro radiation-induced MN levels, and to a lesser extent, the radiation-induced DNA damage assessed by the Comet assay. These data suggest that clinical radiation may provoke genetic instability and/or induce persistent DNA damage in normal cells of cancer patients, thus leading to increased levels of MN induction and DNA fragmentation after irradiation in vitro. Therefore, care has to be taken when blood samples collected postradiotherapeutically are used to assess the radiosensitivity of cancer patients.

Keywords: DNA damage; DNA repair; peripheral blood lymphocytes; single-cell gel electrophoresis

Breast cancer is the common type of malignancy in females, accounting for approximately 21% of all cancer cases in women worldwide (Parkin et al, 1999). Out of all BC patients, 2% have a strong genetic predisposition, caused by the highly penetrant BRCA1 and BRCA2 genes (Peto et al, 1999). Because these genes cannot account for the overall increased risk in the relatives of BC cases (Baeyens et al, 2002), it was suggested that a substantial proportion of BC patients may be predisposed to cancer through mutations in low penetrance genes (Teare et al, 1994; Roberts et al, 1999; Scott et al, 1999; Scott, 2004), which may be genes involved in DNA damage processing and repair.

Several DNA damage processing and repair pathways constitute a guard system that protects cells against genetic instability and tumorigenesis. Both genetic instability and impaired DNA restitution have been pointed out as factors underlying increased susceptibility to malignancy (for reviews, see Lengauer et al, 1998; Thompson and Schild, 2002). The biological importance of genetic instability and DNA repair mechanisms in cancer development is particularly well illustrated by the autosomal recessive disorders ataxia telangiectasia, Fanconi anaemia and Nijmegen breakage syndrome. These chromosome breakage syndromes are characterised by various defects in DNA repair, predisposition to different forms of malignancy and increased radiosensitivity (for a review, see Carney 1999). Apart from these rare syndromes, the deficient DNA repair capacity has been proposed to be a predisposing factor in familial BC and in some sporadic BC cases (Parshad et al, 1996). Genomic instability has also been described for various hereditary cancers including hereditary BC (Rothfuß et al, 2000; Baeyens et al, 2002).

Genomic instability and DNA repair capacity have been analysed in numerous population-based studies using a variety of assays that assess chromosomal aberrations, sister chromatid exchanges, micronuclei (MN), DNA fragmentation by means of the Comet assay, etc. Some of these studies have revealed reduced DNA repair capacity in peripheral blood mononuclear cells (PBMCs, exposed in vitro to ionising radiation (IR) or UV) from BC patients, as evaluated by the chromosome aberration assay (Rigaud et al, 1990; Helzlsouer et al, 1995; Parshad et al, 1996) as well as by the MN test (Scott et al, 1998, 1999; Baeyens et al, 2002). Furthermore, a series of studies have found elevated G2 chromosomal radiosensitivity in the blood cells from BC patients (Baria et al, 2001; Riches et al, 2001; Baeyens et al, 2002). Interestingly, there has been no correlation between the G2 chromosome aberration and G0 MN assays performed simultaneously on cells from 80 patients, which were either G2 (38%) or...
G0 (21%) sensitive, with only 4% sensitive in both assays (Scott et al., 1999). Prompted by the finding that the G2 chromosome aberration test yields a larger portion of sensitive patients than the G0 MN test (Scott et al., 1999) and by the potency of the G2 metaphase test in assessing cytogenetic responses (Parshad et al., 1996; Baria et al., 2001; Riches et al., 2001; Baeyens et al., 2002), we applied here a modified G2 MN test. Unlike the conventional G0 MN test, our method involved cells stimulated with phytohemagglutinin (PHA) for 48 h prior to irradiation, as commonly used for assessing G2 chromosomal aberrations (Scott et al., 1998).

Another convenient test to evaluate both genetic instability and DNA repair capacity is the single-cell gel electrophoresis or Comet assay (Singh et al., 1988; Olive et al., 1990). We have shown recently that this method allows the discrimination of carriers of chromosome instability syndromes including ataxia telangiectasia and Fanconi anaemia (Djuzenova et al., 1999, 2001). In addition, using the Comet assay, we have found the background and induced DNA damage in the peripheral blood lymphocytes from BC patients to be similar to that in control individuals (Djuzenova et al., 1999). Consistent with these data, nonirradiated lymphocytes from patients with multiple tumours (Müller-Vogt et al., 2003), lung cancer (Rajaee-Bebahani et al., 2001) and BC (Alapetite et al., 1999) have also been reported to exhibit the same range of DNA damage as control cells. Similarly, no difference has been revealed by the Comet assay between cells from control subjects and patients with BRCA1 mutation, after irradiation with 2 Gy in vitro (Rothfuß et al., 2000).

In contrast to the above findings, increased basal as well as elevated radiation- and doxorubicin-induced DNA damage levels have been observed in the blood lymphocytes from BC patients (Blasiak et al., 2004; Colleu-Durel et al., 2004; Hussien et al., 2005).

Despite extensive studies into the relationship between cellular radiation tests, cancer risk and clinical radiation reaction, a convincing opinion has not been formed yet. The discrepancies cited above prompted us to explore whether the Comet and modified G2 MN assays are able to predict the clinical radiation reaction of BC patients and to discriminate them from healthy subjects. In addition, we analysed the influence of previous radiotherapy (RT) on the radiation response of cells in vitro. We examined both baseline and radiation-induced DNA damage in PBMCs from a much sizeable group of 50 unselected BC patients compared to that studied before (Djuzenova et al., 1999). PBMCs from a small group of cancer patients with an adverse early skin reaction to RT have also been included.

**MATERIALS AND METHODS**

**Subjects**

The assay was performed on PBMCs isolated from three groups of individuals: (1) a group (n = 50) of unselected BC patients who were prospectively involved in the study and their blood samples were collected before clinical irradiation; (2) a group of cancer patients with an adverse early skin reaction (radiation therapy oncology group (RTOG) grades 2 and 3) to RT, who were retrospectively involved in the study, hereafter designated as ‘SC, sensitive cases’ and included seven patients with BC, one with tongue carcinoma (TC) and one with plasmacytoma (PC). Blood sampling was carried out during or after cessation of RT; and (3) a group of apparently healthy donors (n = 16), mainly hospital personnel and their relatives. To our knowledge, none of the healthy controls was previously exposed to radiation. All patients and healthy donors were asked to complete a questionnaire on their medical histories and lifestyles, including genetic diseases, medication, alcohol consumption, smoking, etc. Patients receiving chemotherapy prior to RT were excluded. The study was approved by the University of Würzburg Ethics Committee and all patients and donors gave informed consent.

Radiotherapy treatment of cancer patients was performed by means of a 6 MV linear accelerator (Siemens, Concord, CA, USA) at a dose rate of 2 Gy min⁻¹. All BC patients received a tangential irradiation of the whole breast, with lateral and medial wedge fields. The regimen comprised a total dose of 50 or 60 Gy with a fractionation dose of 2 Gy five times a week. The early skin reaction to RT developing in the skin within the radiation field of the breast was used as an indicator for clinical radiosensitivity according RTOG score (Cox et al., 1995).

**Blood sampling and isolation of cells**

PBMCs were separated from the heparinised blood samples by density-gradient centrifugation using Ficoll–Histopaque 1077 (Sigma 1077–1, Deisenhofen, Germany) according to the manufacturer’s instructions. Peripheral blood mononuclear cells were washed twice with Ca²⁺- and Mg²⁺-free physiological phosphate-buffered saline (PBS; Sigma D-8537) and finally resuspended in the freezing medium containing RPMI 1640 (Sigma R-8758), 10% foetal calf serum and 10% dimethyl sulphoxide, and stored frozen in a liquid nitrogen until analysis.

**Alkaline Comet assay (slide method)**

The Comet assay was performed under alkaline conditions following a modified protocol initially reported elsewhere (Singh et al., 1988; Djuzenova et al., 1999, 2001). Fully frosted microscope slides (SuperFrost Plus®, Menzel GmbH, Braunschweig, Germany) were dipped up to one-fourth the frosted area in a hot 0.9% normal-melting-point agarose (Roth, 2268.2; Karlsruhe, Germany) in PBS. The slides were air-dried and stored at room temperature until needed. A measure of 80 μl of cell/agarose suspension (10 μl of cell suspension containing about 10⁸ cells was mixed with 70 μl of 0.6% low-melting-point agarose, Roth, 6351.1, in PBS) was placed over the first agarose layer and allowed to solidify under a coverslip. After irradiation, coverslips were removed, the slides were gently immersed in a cold lysis solution (2.5 M NaCl, 100 mM ethylenediaminetetraacetic acid (EDTA), 10 mM Tris, 1% sodium sarcosinate, pH was adjusted to 10 with NaOH, 10% dimethyl sulphoxide and 1% Triton X-100 added just before use) for 1 h at 4°C to lyse the cells and to permit DNA unfolding. The microscope slides were then transferred to the horizontal gel electrophoresis unit filled with fresh, chilled electrophoresis buffer (300 mM NaOH, 1 mM EDTA, pH 13.5) to a level of about 0.2 cm above the slides and left for 20 min to allow unwinding of DNA before electrophoresis. Electrophoresis was conducted for the next 20 min at 22 V (0.83 V cm⁻¹). The slides were then drained, placed on a tray and flooded slowly with three changes of a neutralisation buffer (0.4 M Tris, pH 7.5), each for 5 min, to remove alkali. The slides were then stained with propidium iodide (Sigma P-4170, 10 μg ml⁻¹ solution in PBS), 50 μl per slide, covered with a coverslip and placed in a humidified air-tight container to prevent drying of the gel, and were analysed within 24 h.

**In vitro X-ray irradiation for comet assay**

At 2 h prior to irradiation, cells were thawed, centrifuged and resuspended in 1 ml of complete growth medium (CGM), consisting of RPMI 1640, supplemented with 10% foetal calf serum, 1% nonessential amino acids, 1 mM sodium pyruvate, 2 mM l-glutamine and penicillin/streptomycin (100 U ml⁻¹ and 100 μg ml⁻¹, respectively). The final cell density of PBMCs was adjusted to 1 × 10⁶ cells ml⁻¹ and the samples were placed at 37°C in a 5% CO₂ incubator. X-irradiation was performed using a 6 MV Siemens linear accelerator (Siemens, Concord, CA, USA) at a dose rate of 2 Gy min⁻¹. Cells embedded in agarose were irradiated on slides on crushed ice and were then placed in ice-cold lysis buffer (see below) or in CGM at 37°C in a water bath for specified times.
prior to lysis. Nonirradiated cells were treated in similar way (but at a zero radiation dose).

Comet capture and analysis

Propidium iodide-stained electropherograms were examined in an epifluorescent microscope (Leica, DMLB, excitation filter: 515–560 nm; barrier filter: 590 nm) attached to a black and white CCD video camera (Cohu Electronics, San Diego, CA, USA), which was connected to a PC equipped with an image analysis software Komet 5.5. (Kinetic Imaging Ltd, Liverpool, UK). Between 75 and 100 randomly captured cells from each slide were analysed at each sampling time. Occasional dead cells, superimposed cells and cells on the edge of the gels were avoided.

Several features for each cell were evaluated by the software package, but the ‘tail moment’ (TM) was used here to quantitate the extent of DNA damage (Olive et al, 1990). The TM value (given in arbitrary units) is defined as the product of the percentage of DNA in the comet tail and the tail length. For each cell sample, the TM data were plotted vs time and fitted to a monoexponential function:

\[ \text{TM}(t) = \text{TM}_0 \exp\left(-\frac{t}{\tau_{0.5}}\right) + \text{TM}_R \]

where \( t \) is the incubation time after X-ray exposure; TM0 and TMR are the initial repairable TM and residual (i.e. irreparable) TM, respectively; and \( \tau_{0.5} \) is the repair half-time, that is, the time required for cells to restitute 50% of the DNA damage. The total initial TMt (\( t = 0 \)) is given by the sum: TMt = TM0 + TMR.

MN test

The MN assay was performed essentially according to Fenech (1993) with slight modifications. Peripheral blood mononuclear cells (2–5 \times 10^6 ml^-1) were incubated in CGM containing 5 \mu g ml^-1 PHA (Sigma L-9132) for 2 days to stimulate the cell cycle progression. At 1 h before irradiation, cytochalasin B (5 \mu g ml^-1, Sigma C-6762) was added to prevent cytokinesis, which resulted in the appearance of binucleated cells (BNCs). After irradiation with a single dose of 1, 2, 3 and 4 Gy, the cells were cultured for additional 24 h, brought onto glass slides by cytopsin centrifugation, fixed in cold methanol (–20°C, 1 h) and finally stained with acridine orange (62.5 \mu g ml^-1, Sigma A-4921) as described elsewhere (Stopper et al, 2005). The percentage of BNCs containing MN and the total numbers of MN per a single BNC were scored in 1000 BNCs using a \times 400 magnification according the criteria published elsewhere (Fenech and Morley, 1985a). In the version of the MN test used here, PBMCs were first stimulated with PHA (48 h) and then irradiated, so it was a G2 MN test as compared to the usually performed G0 MN test (Scott et al, 1998; Baeyens et al, 2002).

Statistics

Data are presented as mean (\pm s.d.). Mean values were compared by the Student’s t-test. The threshold of statistical significance was set at \( P < 0.05 \). Statistics and fitting of experimental curves were performed with the program Origin 5.0 (Microcal, Northampton, MS, USA).

RESULTS

Comet assay

The damage to DNA and its repair kinetics were evaluated up to 40 min after exposure to 5 Gy of X-rays, with a step of 10 min. The Comet TM (see Materials and Methods) was used to quantify the

Figure 1 DNA damage assessed by means of the Comet assay in nonirradiated (A) as well as in irradiated (B–D) PBMCs derived from unselected BC patients (circles) and radiation-sensitive (unfilled down triangles) cancer patients compared with the cells from apparently healthy donors (squares). Initial (B), residual (C) DNA damage and the repair half-time constants (D) were assessed in PBMCs after irradiation with 5 Gy in vitro. Filled triangles represent the mean values for the respective group. ‘NS’ indicates that the difference was not highly significant (\( P > 0.05 \)). To facilitate visual comparison, the dashed line is drawn through the mean value of the group of healthy donors. Star and diamond represent the data for patients 016 and 021 who revealed an adverse skin reaction after RT.
extent of DNA damage. The mean TM data were plotted as functions of time (data not shown) and fitted to equation (1) using the least-squares method. From the best fits, the values of the initial (TM\(_{i}\)) and residual (TM\(_{r}\)) tail moment, as well as the repair half-time (t\(_{0.5}\)) were determined for the cell samples from each tested individual (Figure 1).

The fitted parameters of DNA damage repair curves for each individual, as well as the age, sex, clinical and smoking status, are given in Table 1, from which the following trends are obvious (see also Figure 1). Although nonirradiated cells of some cancer patients exhibited noticeably higher baseline amounts of DNA fragmentation, the mean values of background DNA damage were similar in the three tested groups of individuals (Figure 1A). Likewise, after irradiation in vitro, the Comet assay did not reveal any differences among the three groups in terms of their initial (Figure 1B) and residual levels of DNA damage (Figure 1C) as well as in the DNA repair kinetics (Figure 1D), which may be in part due to the strong interindividual variability.

Out of 50 prospectively recruited BC patients, only two (016 and 021) exhibited an increased early skin reaction to RT (both grades 2 and 3 according RTOG score) so the group of ‘unselected BC’ patients could be also viewed as normally reacting patients.

### Table 1: DNA damage measured by the Comet assay in PBMCs isolated from blood of apparently healthy donors (N), unselected BC patients and cancer patients with adverse skin reaction to RT after exposure to 5 Gy of X-irradiation in vitro

| Subject | Age (years) | Sex | Smoking status | Clinical status with respect to cancer, skin reaction to RT | 0 Gy, TM (AU) | Total initial TM, TM\(_{i}\) (AU) | Residual TM, TM\(_{r}\) (AU) | Repair half-time (min) |
|---------|-------------|-----|----------------|----------------------------------------------------------|--------------|---------------------------------|----------------------------|------------------------|
| N-1     | 26          | F   | —              | ND                                                      | 0.44         | 7.11                            | 0.69                       | 5.81                   |
| N-2     | 27          | F   | —              | ND                                                      | 0.38         | 11.39                           | 2.20                       | 2.23                   |
| N-3     | 39          | M   | —              | ND                                                      | 0.60         | 11.97                           | 0.76                       | 4.51                   |
| N-4     | 38          | F   | —              | ND                                                      | 0.48         | 7.34                            | 0.80                       | 7.39                   |
| N-5     | 51          | F   | —              | ND                                                      | 0.57         | 10.37                           | 0.61                       | 3.80                   |
| N-6     | 32          | M   | 10/day         | ND                                                      | 0.69         | 11.17                           | 0.81                       | 4.40                   |
| N-7     | 31          | M   | —              | ND                                                      | 0.37         | 9.76                            | 0.97                       | 2.64                   |
| N-8     | 25          | M   | —              | ND                                                      | 0.44         | 13.42                           | 0.60                       | 5.74                   |
| N-9     | 24          | M   | —              | ND                                                      | 0.26         | 14.22                           | 0.73                       | 5.08                   |
| N-10    | 27          | F   | —              | ND                                                      | 0.45         | 8.40                            | 0.74                       | 3.89                   |
| Mean    | 41          |     |                |                                                          | 0.49         | 10.30                           | 1.0                        | 4.60                   |
| ±s.d.   | 18          |     |                |                                                          | 0.13         | 2.0                             | 0.45                       | 1.82                   |

**BC patients**

| Subject | Age (years) | Sex | Smoking status | Clinical status with respect to cancer, skin reaction to RT | 0 Gy, TM (AU) | Total initial TM, TM\(_{i}\) (AU) | Residual TM, TM\(_{r}\) (AU) | Repair half-time (min) |
|---------|-------------|-----|----------------|----------------------------------------------------------|--------------|---------------------------------|----------------------------|------------------------|
| 001     | 62          | F   | 5–10/day       | BC, grade 2                                              | 0.62         | 9.82                            | 1.38                       | 4.30                   |
| 002     | 63          | F   | —              | BC, grade 2                                              | 1.09         | 12.34                           | 1.41                       | 6.89                   |
| 003     | 68          | F   | —              | BC, grade 1                                              | 0.97         | 8.61                            | 0.79                       | 4.71                   |
| 004     | 65          | F   | —              | BC, grade 1                                              | 0.42         | 12.74                           | 1.00                       | 5.70                   |
| 005     | 58          | F   | —              | BC, grade 2                                              | 0.36         | 12.52                           | 1.07                       | 4.41                   |
| 006     | 79          | F   | —              | BC, grade 1                                              | 0.27         | 9.71                            | 0.62                       | 4.50                   |
| 008     | 64          | F   | —              | BC, grade 1                                              | 0.39         | 15.05                           | 0.69                       | 6.27                   |
| 009     | 47          | F   | 10/day         | BC, grade 1                                              | 0.29         | 10.14                           | 0.75                       | 10.45                  |
| 010     | 75          | F   | —              | BC, grade 2                                              | 0.83         | 17.96                           | 1.03                       | 3.67                   |
| 012     | 58          | F   | —              | BC, grade 1                                              | 0.42         | 11.99                           | 1.30                       | 4.46                   |
| 013     | 55          | F   | —              | BC, grade 1                                              | 0.48         | 10.81                           | 1.29                       | 2.11                   |
| 014     | 73          | F   | —              | BC, grade 1                                              | 0.55         | 6.36                            | 0.83                       | 7.04                   |
| 015     | 72          | F   | —              | BC, grade 1                                              | 0.55         | 6.36                            | 0.83                       | 7.04                   |
| 016     | 66          | F   | —              | BC, grades 2 and 3                                       | 0.71         | 13.87                           | 1.01                       | 4.04                   |
| 017     | 56          | F   | —              | BC, grade 1                                              | 0.56         | 9.18                            | 0.80                       | 5.28                   |
| 018     | 55          | F   | 10–15/day      | BC, grade 0 and 1                                        | 0.36         | 6.03                            | 0.83                       | 3.46                   |
| 019     | 69          | F   | —              | BC, grade 0 and 1                                        | 0.50         | 6.25                            | 0.26                       | 9.27                   |
| 020     | 75          | F   | —              | BC, grade 0 and 1                                        | 0.45         | 7.40                            | 0.93                       | 5.86                   |
| 021     | 69          | F   | —              | BC, grades 2 and 3                                       | 0.32         | 6.08                            | 0.60                       | 3.23                   |
| 022     | 62          | F   | —              | BC, grade 1                                              | 0.27         | 10.13                           | 0.76                       | 3.87                   |
| 023     | 63          | F   | —              | BC, grade 1                                              | 0.45         | 8.92                            | 1.19                       | 6.60                   |
| 024     | 70          | F   | —              | BC, grade 1                                              | 0.34         | 7.25                            | 1.25                       | 2.77                   |
| 025     | 54          | F   | 2–5/day        | BC, grade 1                                              | 0.33         | 5.90                            | 0.81                       | 4.41                   |
| 026     | 74          | F   | —              | BC, grade 0                                              | 0.26         | 4.78                            | 0.74                       | 4.13                   |
| 027     | 38          | F   | —              | BC, grade 2                                              | 0.55         | 12.36                           | 0.64                       | 8.25                   |
| 028     | 59          | F   | —              | BC, grade 1                                              | 0.94         | 13.81                           | 1.52                       | 9.56                   |
| 029     | 67          | F   | —              | BC, grade 2                                              | 0.45         | 9.89                            | 0.58                       | 5.75                   |
| 030     | 63          | F   | —              | BC, grade 1                                              | 0.78         | 12.65                           | 1.21                       | 4.21                   |
| 031     | 47          | F   | 15–20/day      | BC, grade 1                                              | 0.69         | 14.58                           | 2.63                       | 4.20                   |
| 032     | 68          | F   | —              | BC, grade 0                                              | 0.73         | 14.65                           | 2.37                       | 3.29                   |
| 033     | 70          | F   | —              | BC, grade 1                                              | 0.56         | 8.10                            | 0.66                       | 9.93                   |
| 034     | 75          | F   | —              | BC, grade 1                                              | 0.78         | 8.59                            | 1.0                        | 7.02                   |
However, only for one of them (Figure 1B, star), the increased clinical radiosensitivity, correlated with a somewhat higher initial DNA damage level detected by the Comet assay. Other parameters of the Comet assay on the cells from these two patients did not deviate significantly from controls.

### MN test

In addition to the Comet assay, the cell samples were analysed by a cytochalasin-blocked MN test (Fenech and Morley, 1985a) with a minor modification concerning mitogen stimulation. This test represents a well-established assay for biomonitoring human populations as an indicator of genetic instability and radiation damage (Müller et al, 2003). Using the G2 MN test, both percentage of BNCs with MN (Figures 2, 3, 5) and total numbers of MN per cell were scored in a total number of 1000 BNCs with MN (Figures 2, 3, 5) and total numbers of MN per cell.

### Table I (Continued)

| Subjectc | Age (years) | Sex | Smoking statusd | Clinical status with respect to cancer, skin reaction to RTd | 0 Gy, TM (AU) | Total initial TM, TMf (AU) | Residual TM, TMR (AU) | Repair half-time (min) |
|-----------|-------------|-----|----------------|-------------------------------------------------------------|--------------|---------------------------|----------------------|----------------------|
| 035       | 54          | F   | —              | BC, grade 1                                                | 0.41         | 11.68                     | 1.11                 | 4.45                 |
| 036       | 48          | F   | —              | BC, grade 1                                                | 0.31         | 9.27                      | 1.07                 | 3.17                 |
| 037       | 58          | F   | —              | BC, grade 1                                                | 0.34         | 6.26                      | 0.65                 | 4.09                 |
| 038       | 75          | F   | 2–5/day        | BC, grade 1                                                | 0.37         | 11.21                     | 1.32                 | 3.38                 |
| 039       | 60          | F   | —              | BC, grade 2                                                | 0.47         | 13.26                     | 1.21                 | 4.30                 |
| 040       | 54          | F   | —              | BC, grade 2                                                | 0.67         | 12.7                      | 1.45                 | 4.52                 |
| 041       | 45          | F   | —              | BC, grade 1                                                | 0.41         | 12.53                     | 1.35                 | 4.40                 |
| 042       | 57          | F   | —              | BC, grade 1                                                | 0.66         | 10.61                     | 0.88                 | 6.33                 |
| 043       | 41          | F   | —              | BC, grade 2                                                | 0.33         | 8.05                      | 0.89                 | 3.76                 |
| 044       | 67          | F   | —              | BC, grade 1                                                | 0.65         | 11.1                      | 0.87                 | 2.99                 |
| 045       | 61          | F   | —              | BC, grade 0 and 1                                          | 0.31         | 13.07                     | 1.09                 | 6.22                 |
| 046       | 69          | F   | —              | BC, grade 1                                                | 0.27         | 9.19                      | 0.43                 | 7.31                 |
| 047       | 55          | F   | 6–8/day        | BC, grade 2                                                | 0.34         | 7.93                      | 0.48                 | 6.10                 |
| 048       | 61          | F   | —              | BC, grade 2                                                | 0.64         | 15.18                     | 1.52                 | 7.02                 |
| 049       | 71          | F   | —              | BC, grade 1                                                | 0.51         | 10.17                     | 0.81                 | 5.47                 |
| 050       | 60          | F   | 20/day         | BC, grade 1                                                | 0.40         | 8.96                      | 1.13                 | 3.94                 |
| 051       | 43          | F   | 2–3/day        | BC, grade 2                                                | 0.39         | 9.26                      | 1.02                 | 3.26                 |
| 052       | 56          | F   | —              | BC, grade 1                                                | 0.31         | 15.43                     | 1.02                 | 5.42                 |
| Mean      | 61          | F   | —              | BC, grade 1                                                | 0.49         | 10.50                     | 1.02                 | 5.38                 |
| ± s.d.    | 10          | F   | —              | BC, grade 1                                                | 0.20         | 3.0                       | 0.43                 | 2.23                 |

### Cancer patients with adverse skin reaction to RT

| Subjectc | Age (years) | Sex | Smoking statusd | Clinical status with respect to cancer, skin reaction to RTd | 0 Gy, TM (AU) | Total initial TM, TMf (AU) | Residual TM, TMR (AU) | Repair half-time (min) |
|-----------|-------------|-----|----------------|-------------------------------------------------------------|--------------|---------------------------|----------------------|----------------------|
| SC1       | 43          | F   | —              | BC, grades 2 and 3                                          | 0.29         | 8.52                      | 0.73                 | 7.20                 |
| SC2       | 50          | M   | —              | BC, grades 2 and 3                                          | 2.18         | 9.71                      | 1.77                 | 5.51                 |
| SC3       | 49          | F   | 5–10/day       | BC, grades 2 and 3                                          | 1.0          | 9.15                      | 0.79                 | 10.09                |
| SC4       | 49          | M   | —              | BC, grades 2 and 3                                          | 0.51         | 7.74                      | 1.13                 | 5.29                 |
| SC5       | 64          | M   | —              | BC, grades 2 and 3                                          | 0.31         | 10.77                     | 1.16                 | 2.17                 |
| SC6       | 52          | F   | 2–5/day        | BC, grade 3                                                | 0.61         | 6.87                      | 1.01                 | 5.50                 |
| SC7       | 49          | F   | —              | BC, grades 2 and 3                                          | 0.29         | 12.08                     | 0.74                 | 5.40                 |
| SC8       | 63          | F   | —              | BC, grades 2 and 3                                          | 0.59         | 7.02                      | 1.28                 | 2.74                 |
| SC9       | 69          | F   | —              | BC, grades 2 and 3                                          | 0.36         | 16.92                     | 1.38                 | 2.35                 |
| Mean      | 54          | F   | —              | BC, grades 2 and 3                                          | 0.68         | 9.9                       | 1.1                  | 5.14                 |
| ± s.d.    | 9           | F   | —              | BC, grades 2 and 3                                          | 0.61         | 3.2                       | 0.3                  | 2.53                 |

BC = breast cancer; F = female; M = male; N = normal; ND = not determined; PBMC = peripheral blood mononuclear cells; PC = plasmacytoma; RT = radiotherapy; SC = sensitive case; TC = tongue carcinoma. Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Significance was established using Student’s t-test. *P compares the differences between tested group and apparently healthy individuals. NS indicates that the difference was not highly significant (P > 0.05). Bold fonts indicate the unselected BC patients who revealed an adverse skin reaction to RT. Case number was according to our files. a'—' means nonsmoker, the numbers indicate the amounts of smoked cigarettes per day. bEarly skin reaction according RTOG score (Cox et al, 1995). RTOG grade: 1 – follicular, faint or dull erythema, dry desquamation; 2 – tender or bright erythema, moderate oedema; 3 – confluent, moist desquamation, pitting oedema; 4 – ulceration, haemorrhage, necrosis.

As an extension of Figure 2B, Figure 3 illustrates the radiation dose dependences of MN induction averaged through each tested group of individuals. The dose–response curve of MN induction in cells from cancer patients with an adverse skin reaction was significantly higher than in both control and unselected BC group. The latter two groups exhibited similar dose–response slopes in the G2 MN test.

In the case of two BC patients (016 and 021) who developed an increased early skin reaction to RT (Figure 2A, star and diamond), the mean spontaneous MN yields in their blood cells were similar to that in control. However, after in vitro irradiation, cells derived from one of them (patient 021) showed a somewhat higher rate of MN induction (Figure 2B, diamond). The mean spontaneous MN yields in their blood cells were similar to that in control. However, after in vitro irradiation, cells derived from one of them (patient 021) showed a somewhat higher rate of MN induction. As an extension of Figure 2B, Figure 3 illustrates the radiation dose dependences of MN induction averaged through each tested group of individuals. The dose–response curve of MN induction in cells from unselected BC patients (Figure 3, circles) is similar to that obtained for control cells (Figure 3, squares). On the other hand, cells from cancer patients with an adverse skin reaction to RT (Figure 3, ‘SC’, triangles) showed significantly higher MN induction levels compared to controls and unselected BC patients. As there was an increased amount of spontaneous MN in cells from radiation-sensitive patients (see also Figure 2A), we additionally normalised the dose–response data by subtracting the mean slope of MN induction in cells from cancer patients with an adverse skin reaction to RT.
As mentioned above, blood samples of cancer patients with an adverse skin reaction to RT (group 2 in Materials and Methods) were collected during or after clinical irradiation. In order to investigate the influence of previous RT on the radiation response of patients’ cells in vitro, blood samples from five unselected BC patients were taken before, during (at 20 and 40 Gy) and after (50–60 Gy of cumulative RT dose) clinical irradiation and analysed by the Comet and MN assays. The Comet assay applied after 5 Gy in vitro revealed that the initial DNA fragmentation rose with increasing cumulative dose of RT in cells of four out of five tested patients (Figure 4A). Unlike the initial DNA damage, no conclusions could be drawn about the influence of previous RT on the residual DNA damage and repair half-time (Figure 4B and C, respectively), mainly because of the wide individual variability of these parameters. In addition, the background DNA damage level (i.e. tail moment at 0 Gy in vitro) remained unchanged after clinical irradiation (data not shown).

The G2 MN assay of the same cell probes shown in Figure 4 revealed that previous RT exerted strong effects on both baseline and in vitro radiation induced MN yields (Figure 5). Thus, for a given radiation dose in vitro (0–4 Gy), the mean MN frequencies grew steadily with increasing cumulative RT dose for all five tested BC patients (Figure 5A–E).

DISCUSSION

In this study, peripheral blood cells isolated from (1) unselected BC patients, (2) cancer patients with an adverse early skin reaction to RT, and (3) healthy individuals were analysed for their DNA fragmentation using the Comet assay. The analysis of both nonirradiated and in vitro-irradiated cell samples did not reveal any differences in the background or radiation-induced DNA damage levels among the three groups. There was a trend toward an increased background level in the cells from both groups of cancer patients, but this failed to reach statistical significance. The Comet data obtained here are in agreement with the findings that the baseline DNA damage levels in nonirradiated peripheral blood lymphocytes from patients with multiple tumours (Müller-Vogt et al., 2003), lung cancer (Rajaei-Bebahaní et al., 2001) and breast cancer (Alapetite et al., 1999) are similar to healthy controls. Our results, although without accounting for BRCA1 and BRCA2 mutations, but on a sizeable sample (n = 50) of unselected BC patients, are also in line with the finding of Rothfuß et al. (2000) that the Comet assay has not revealed any difference between the in vitro-irradiated cells from four patients with BRCA1 mutation and those from four control subjects.
Genetic instability in breast cancer

Figure 4  Effects of foregoing RT on the radiation response in vitro of cells from five breast cancer patients (017, 018, 019, 020 and 022, see Table 1) with normal clinical radiosensitivity assessed by the Comet assay. A–C) The initial and the residual DNA damage, and the repair half-time constants, respectively. Data were averaged through 75 cells from a given individual per dose and time point. Blood samples were collected before, during (20 and 40 Gy) and after cessation (50–60 Gy) of RT. Bars for the means have been omitted for clarity.

On the other hand, our results disagree with those of Colleu-Durel et al. (2004) and Hussien et al. (2005), who have found increased levels of both basal and radiation-induced DNA damage in cells from BC patients, as compared to healthy controls. The reasons for the discrepancy might reside in the patients’ and controls’ cohorts, cancer stage, treatment prior to blood sampling, arbitrary determined cut off values, experimental protocols as well as in interlaboratory variability. Thus, in contrast to the present and several other studies (Alapetite et al., 1999; Rothfuß et al., 2000; Müller-Vogt et al., 2003), in which healthy individuals were used as references, the control group in Hussien et al. (2005) includes patients with the benign breast disease. Besides this, even if the same version of the alkaline Comet assay (Singh et al., 1988) was used here and elsewhere (Colleu-Durel et al., 2004; Hussien et al., 2005), the quantitative TM data appear to differ greatly between laboratories. Thus, the TM values of 7.74 and 14.67 in nonirradiated cells from control and BC patients, respectively, obtained by Colleu-Durel et al. (2004) are larger some 20–30-fold than the TM values of 0.47 and 0.45 presented here in Figure 1A. For comparison, the TM values of 1.4 and 1.21 have been found, respectively, for bladder cancer patients and controls (Schabath et al., 2003), whereas TM values of about three have been obtained for both breast cancer patients and controls by Alapetite et al. (1999).

The second screening test used here was the MN assay. Unlike the usual version of the MN test, which involves irradiation of quiescent G0 cells followed by mitogen stimulation (Scott et al., 1998; Burrill et al., 2000; Baeyens et al., 2002), in the present study, the cells were stimulated with PHA for 48 h prior to irradiation, as commonly used for assessing G2 chromosomal aberrations (Scott et al., 1998). We found that the mean frequencies of both spontaneous and radiation-induced MN in PBMCs from unselected BC patients were similar to those in control. Consistent with the G2 MN data presented here, the G0 MN assay also has failed to discriminate a group of cervical, head and neck cancer patients from healthy individuals (Slonina et al., 2000). In addition, the radiomimetic drug bleomycin induces similar rates of chromatid breaks in lymphocytes from BC patients and from healthy controls (Hsu et al., 1989).

On the other hand, the data for the group of unselected BC patients obtained here using the G2 MN test seem to disagree with those from several studies (Scott et al., 1998; Burrill et al., 2000; Baeyens et al., 2002), in which the G0 MN test has, in which the G0 MN test has, increased radiosensitivity in cells from BC patients compared to healthy controls (reviewed in Speit and Trenz, 2004). The apparent conflict, however, can be explained by differences in both experimental and statistical approaches used here and elsewhere (Scott et al., 1998; Burrill et al., 2000; Baeyens et al., 2002). Firstly, we used a modified G2 version of the MN test instead of the classic G0 MN assay. Secondly, we compared the mean values of groups rather than the data ranges. Thirdly, we did not set any arbitrary cut off values. Finally, the control and patients’ cohorts differ markedly among studies.

We also found that blood cells from cancer patients with an adverse early skin reaction to RT displayed increased frequencies of both spontaneous and radiation-induced MN compared to the cells from apparently healthy donors and unselected BC patients (Figures 2 and 3). This result is in agreement with the findings that MN levels are elevated in cells from BC patients with known genetic predisposition (Rothfuß et al., 2000; Baeyens et al., 2002). It has to be noted, however, that in our study the radiation-sensitive cancer patients were recruited based on the knowledge of their clinical reaction to RT, so that blood sampling was performed during or after cessation of RT. This fact raised an important question whether RT itself affects the outcome of in vitro tests. To check this possibility, we further analysed blood samples (of five patients) collected prior, during (20 and 40 Gy) and after (50–60 Gy) cessation of RT. A striking effect of the radiation in vivo on the spontaneous and radiation-induced MN yields in vitro was observed in all five tested patients (Figure 5). These data suggest that clinical radiation might have provoked genetic instability and/or induced persistent (nonrepaired) DNA damage in the normal cells of cancer patients, thus leading to increased levels of MN induction and DNA fragmentation after irradiation in vitro. Our data agree with the observations that MN levels rise with increasing cumulative RT dose in cancer patients (Fenech et al., 1990; Cao et al., 2002), although some studies report a lack of difference in the G2 chromosomal radiosensitivity between pre- and post-therapy samples (Roberts et al., 1999; Baeyens et al., 2002). Furthermore, the increased frequency of spontaneous MN in cells from BC patients has been suggested to be caused, at least partly, by previous radio- and/or chemotherapy (Baeyens et al., 2002), which is in agreement with our data presented in Figure 5.
Unlike the MN test, the Comet assay revealed only a weak correlation between the initial DNA damage and cumulative RT doses (Figure 4A), whereas other parameters, including the residual DNA damage and repair half-time constants, do not allow any conclusions to be made, mainly because of the wide data scattering. In addition, the Comet assay did not detect any changes in the background DNA fragmentation in peripheral lymphocytes from BC patients subjected to RT (data not shown).

It may be argued that in the present study the small control group (an average age of 41 ± 18 years) was much younger than each tested patients’ group (mean age of 61 ± 10 and 55 ± 9). However, it has been shown earlier that while the basal levels of DNA damage in the Comet assay are independent of the age of the donor, an age-dependent increase in DNA damage has been observed immediately after irradiation (Singh et al., 1990). In addition, a nearly four-fold increase in MN in cultures from 80-year-old donors was measured compared with that in the cultures from newborn donors (Fenech and Morley, 1985b), and an age-dependent increase of 0.58 MN year⁻¹ was found for a female population (Thierens et al., 2000). Taking these data into account, the cells from the much elderly group of BC patients studied here could be expected to exhibit increased levels of both radiation-induced DNA damage and spontaneous MN expression, as compared with those from the younger controls. However, at variance with expectation, there was no significant difference in the induced DNA damage between the group of unselected BC patients and controls (Figures 1 and 2). Likewise, the two groups exhibited similar baseline frequencies of MN expression (Figure 2A). Another point is that our control group includes several males, whereas BC patients’ groups include only females. However, the effect of gender on the outcome of both Comet and MN tests has been reported to be negligible (Garaj-Vrhovac and Kopjar 2003; Hadjidekova et al., 2003).

As fortunately a minority (about 5%) of RT patients develop during or after RT either acute or late radiotoxic responses (Norman et al., 1988), a cohort of 50 prospectively recruited BC...
patients in our study was too small to find several radiation-sensitive patients. Indeed, we observed only two patients exhibiting early skin radiotoxicity during or shortly after RT. Even so, there was a weak correlation of radiation response in vivo with either an increased DNA damage level in Comet assay or an increased MN induction in one or another case. Furthermore, the present study is ongoing, so that potential late effects of RT are still to be analysed and they will be the subject of future follow-up.

In conclusion, neither prospectively recruited BC patients nor sensitive cancer patients with an adverse skin reaction to RT could be identified by the Comet assay. In contrast, the modified G2 MN test detected significantly increased levels of both spontaneous and radiation-induced MN in cells from sensitive cancer patients. However, the G2 MN assay was unable to identify normally reacting BC patients. The increased MN rates in sensitive cancer patients might have been in part a consequence of the previous RT, which was found to affect strongly the outcome of the MN test in vitro. A larger study is required to investigate to what extent RT alters the radiation response of patients' cells in vitro.

ACKNOWLEDGEMENTS

This work was supported by a grant of the Deutsche Krebshilfe.

REFERENCES

Alapetite C, Thirion P, de la Rochefordiere A, Cosset JM, Moustacchi E (1999) Analysis by alkaline comet assay of cancer patients with severe reactions to radiotherapy: definitive rejoining of radioinduced DNA strand breaks in lymphocytes of breast cancer patients. Int J Cancer 83: 83 – 90

Baeyens A, Thierens H, Claes K, Poppe B, Messiaen L, De Ridder L, Vral A (2002) Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J Cancer 87: 1379 – 1385, (doi:10.1038/sj.bjc.6600628)

Baria K, Warren SA, West CM, Scott D (2001) Chromosomal radiosensitivity as a marker of predisposition to common cancers? Br J Cancer 84: 892 – 896, (doi:10.1054/bjc.2000.1701)

Blaizak J, Arabzki M, Krupa R, Wozniak K, Rykala J, Kolacinska A, Morawiec Z, Drzewski J, Zadrozy M (2004) Basal, oxidative and alkaline DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 554: 139 – 148, (doi:10.1016/j.nfmm.2004.04.001)

Burrill W, Barber JB, Roberts SA, Bulman B, Scott D (2000) Heritability of chromosomal radiosensitivity in breast cancer patients: a pilot study with the lymphocyte micronucleus assay. Int J Radiat Biol 76: 1617 – 1619

Cao J, Liu Y, Sun H, Cheng G, Pang X, Zhou Z (2002) Chromosomal aberrations, DNA strand breaks and gene mutations in nasopharyngeal cancer patients undergoing radiation therapy. Mutat Res 504: 85 – 90, (doi:10.1016/S0165-7997(02)00682 – 9)

Carney JP (1999) Chromosomal breakage syndromes. Curr Opin Immunol 11: 443 – 447

Colleu-Durel S, Guitton N, Nourgalieva K, Legue F, Levéque J, Danic B, Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341 – 1346

Djuzenova CS, Rothfuss A, Oppitz U, Speit G, Schindler D, Hoehn H, Fentje M (2001) Response to X-irradiation of Fanconi anemia heterozygous cell assessed by the single-cell gel electrophoresis (Comet) assay. Lab Invest 83: 185 – 192

Djuzenova CS, Schindler D, Stopper H, Hoehn H, Fentje M, Oppitz U (1999) Identification of ataxia-telangiectasia heterozygotes, a cancer prone population, using the single-cell gel electrophoresis (Comet) assay. Lab Invest 79: 699 – 705

Fenech M (1993) The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res 285: 35 – 44

Fenech M, Denham J, Francis W, Morley A (1990) Micronuclei in cytokinesis-blocked lymphocytes of cancer patients following fractionated partial-body radiotherapy. Int J Radiat Biol 57: 373 – 383

Fenech M, Morley AA (1985a) Measurement of micronuclei in lymphocytes. Mutat Res 147: 29 – 36

Fenech M, Morley AA (1985b) The effect of donor age on spontaneous and induced micronuclei. Mutat Res 148: 99 – 105

Garaj-Vrhovac V, Kopjar N (2003) The alkaline Comet assay as biomarker in assessment of DNA damage in medical personnel occupationally exposed to ionizing radiation. Mutagenesis 18: 265 – 271

Hadjidjekeva VB, Bulanova M, Bonassi S, Neri M (2003) Micronucleus frequency is increased in peripheral blood lymphocytes of nuclear power plant workers. Radiat Res 160: 684 – 690

Helmisouer KJ, Harris EL, Prashad R, Fogel S, Bigbee WL, Sanford KK (1995) Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer 64: 14 – 17

Hsu TC, Johnston DA, Cherry LM, Ramkisson D, Schantz SP, Jessup JM, Winn RJ, Shirley L, Furlong C (1989) Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 43: 403 – 409

Hussien MM, McNulty H, Armstrong N, Johnston GP, Spence RAJ, Barnett Y (2005) Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients. Br J Cancer 92: 1524 – 1530, (doi:10.1038/sj.bjc.6602530)

Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643 – 649

Müller WU, Nüsse M, Miller BM, Slavotinek A, Biagi S, Streff C (2003) Micronuclei: a biological indicator of radiation damage. Mutat Res 566: 163 – 169

Müller-Vogt US, Maurer JEE, Grabenbauer GG, Distel LV, Iro H, Steinhart H (2003) Altered DNA repair capacity in young patients suffering from multiple cancers. Int J Mol Med 11: 669 – 674

Norman A, Kagan AR, Chan SL (1988) The importance of genetics for the optimization of radiation therapy. A hypothesis. Am J Clin Oncol 11: 84 – 88

Olve PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'Comet' assay. Radiat Res 122: 86 – 94

Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827 – 841

Parshad R, Price FM, Bohr VA, Cansens KH, Zajewski JA, Sanford KK (1996) Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 74: 1 – 5

Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Eaton D, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943 – 949

Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Norman A, Kagan AR, Chan SL (1988) The importance of genetics for the optimization of radiation therapy. A hypothesis. Am J Clin Oncol 11: 84 – 88

Rajaei-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Eaton D, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943 – 949

Riches AC, Bryant PE, Steel GM, Gleig A, Robertson AJ, Preece PE, Thompson AM (2001) Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J Cancer 85: 1157 – 1161

Rigaud O, Guedeney G, Duranton I, Leroy A, Doloy MT, Magdelenan H (1999) Genotoxic effects of radiotherapy and chemotherapy on the circulation lymphocytes of breast cancer patients. Mutat Res 429: 25 – 35

Roberts SA, Spreadbrother AB, Bulman B, Barber JBP, Evans DGR, Scott D (1999) Heritability of cellular radiosensitivity: a marker of low-penetration predisposition genes in breast cancer. Am J Hum Genet 65: 784 – 789

Rothfuß A, Schütz P, Bochum S, Volm T, Eberhardt E, Kreienberg R, Vogel W, Speit G (2000) Induced micronucleus frequencies in peripheral

British Journal of Cancer (2006) 94(8), 1194 – 1203 © 2006 Cancer Research UK
lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res 60: 390 – 394
Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng P-J, Wu X (2003) Genetic instability in bladder cancer assessed by the Comet assay. J Natl Cancer Inst 95: 540 – 547
Scott D (2004) Chromosomal radiosensitivity and low penetrance predisposition to cancer. Cytogenet Genome Res 104: 365 – 370
Scott D, Barber JB, Spreadborough AR, Burrill W, Roberts SA (1999) Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. Int J Radiat Biol 75: 1 – 10
Scott D, Barber JB, Levine EL, Burrill W, Roberts SA (1998) Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition? Br J Cancer 77: 614 – 620
Singh NP, Danner DB, Tice RR, Brant L, Schneider EL (1990) DNA damage and repair with age in individual human lymphocytes. Mutat Res 237: 123 – 130
Singh NP, McCoy MT, Tice RR, Schneider E (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184 – 191
Slonina D, Klimek M, Szpytma T, Gasinska A (2000) Comparison of the radiosensitivity of normal-tissue cells with normal-tissue reactions after radiotherapy. Int J Radiat Biol 76: 1255 – 1264
Speit G, Trenz K (2004) Chromosomal mutagen sensitivity associated with mutations in BRCA genes. Cytogenet Genome Res 104: 325 – 332
Stopper H, Hempel K, Reiners C, Vershenya S, Lorenz R, Vukicevic V, Heidland A, Graue J (2005) Pilot study for comparison of reticulocyte-micronuclei with lymphocyte-micronuclei in human biomonitoring. Toxicol Lett 156: 351 – 360, (doi:10.1016/j.toxlet.2004.12.007)
Teare MD, Wallace SA, Harris M, Howell A, Birch JM (1994) Cancer experience in the relatives of an unselected series of breast cancer patients. Br J Cancer 70: 102 – 111
Thierens H, Vral A, Morthier R, Aousalah B, De Ridder L (2000) Cytogenetic monitoring of hospital workers occupationally exposed to ionizing radiation using the micronucleus centromere assay. Mutagenesis 15: 245 – 249
Thompson LH, Schild D (2002) Recombinational DNA repair and human disease. Mutat Res 509: 49 – 78, (doi:10.1016/S0027 – 5107(02)00224 – 5)